A pharmaceutical composition for inhalation comprises aclidinium in the form of a dry powder of a pharmaceutically acceptable salt in admixture with a pharmaceutically acceptable dry powder carrier, and provides a metered nominal dose of aclidinium equivalent to about 200 micrograms aclidinium bromide一種供吸入之藥劑組成物,包括乾粉型態之阿地尼亞(aclidinium)於藥理學上可接受的鹽,並與一藥理學上可接受之乾粉載體相混合,且提供有一相當於約200微克阿地溴銨(aclidinium bromide)之阿地尼亞定量標稱劑量。